Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

  • Bioorg Med Chem Lett. 2004 May 3;14(9):2245-8. doi: 10.1016/j.bmcl.2004.02.015.
Kate F Byth  1 ,  Janet D Culshaw ,  Stephen Green ,  Sandra E Oakes ,  Andrew P Thomas
Affiliations
  • 1. AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
PMID: 15081017 DOI: 10.1016/j.bmcl.2004.02.015
Abstract

Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions of substitution, which allow modification of physical properties and offer the potential for in vivo optimisation.

Products